Citadel Advisors
TARS icon

Citadel Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Citadel Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2M Buy
241,737
+77,740
+47% +$4.97M ﹤0.01% 2941
2026
Q1 		$11.5M Buy
+163,997
New +$11.5M ﹤0.01% 3062
2025
Q4 		– Sell
-43,281
Closed -$2.57M – 14045
2025
Q3 		$2.57M Sell
43,281
-185,965
-81% -$9.16M ﹤0.01% 5577
2025
Q2 		$9.29M Sell
229,246
-763,396
-77% -$34.4M ﹤0.01% 3136
2025
Q1 		$51M Buy
992,642
+913,301
+1,151% +$45.1M 0.01% 1129
2024
Q4 		$4.39M Sell
79,341
-305,126
-79% -$13.9M ﹤0.01% 4168
2024
Q3 		$12.6M Buy
384,467
+176,978
+85% +$4.97M ﹤0.01% 2578
2024
Q2 		$5.64M Sell
207,489
-11,789
-5% -$396K ﹤0.01% 3562
2024
Q1 		$7.97M Buy
219,278
+176,241
+410% +$5.18M ﹤0.01% 3252
2023
Q4 		$871K Buy
43,037
+37,173
+634% +$621K ﹤0.01% 6950
2023
Q3 		$104K Sell
5,864
-131,753
-96% -$2.33M ﹤0.01% 10845
2023
Q2 		$2.49M Buy
137,617
+85,361
+163% +$1.36M ﹤0.01% 4777
2023
Q1 		$657K Buy
52,256
+31,289
+149% +$458K ﹤0.01% 7728
2022
Q4 		$307K Buy
+20,967
New +$347K ﹤0.01% 9264
2022
Q3 		– Sell
-20,873
Closed -$331K – 13585
2022
Q2 		$305K Sell
20,873
-4,228
-17% -$63.5K ﹤0.01% 9768
2022
Q1 		$422K Buy
+25,101
New +$466K ﹤0.01% 9783

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's TARS Position: Q2 2026 in Review

Citadel Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 47% in Q2 2026, buying an estimated $4.97M and bringing the position to 241,737 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

Citadel Advisors first reported a position in TARS in Q1 2022 and has held it in 16 quarters since. The position peaked at $51M in Q1 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Citadel Advisors held 241,737 shares of Tarsus Pharmaceuticals worth $15.2M as of Q2 2026.
  • Citadel Advisors bought 77,740 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $4.97M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2941 holding.
  • Citadel Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Citadel Advisors's Tarsus Pharmaceuticals position peaked at $51M in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.